Wall Street Analysts Think Inogen ( INGN ) Could Surge 49.25%: Read This Before Placing a Bet
The mean of analysts' price targets for Inogen (INGN) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Inogen Stock Gains Following Q2 Earnings Beat, Revenues Up Y/Y
INGN stock rises as Q2 loss narrows and revenue climbs 4% year over year, driven by strong B2B demand despite DTC and rental declines.
Inogen ( INGN ) Reports Q2 Loss, Beats Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of +31.82% and +1.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Masimo ( MASI ) Beats Q2 Earnings and Revenue Estimates
Masimo (MASI) delivered earnings and revenue surprises of +8.13% and +0.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen ( INGN ) Down 0.8% Since Last Earnings Report: Can It Rebound?
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
3 Stocks With Upgraded Broker Ratings to Bet on Amid Uncertainties
Broker upgrades boost URBN, INGN and SWX, with earnings growth and strong Zacks Ranks signaling potential upside despite market volatility.
Inogen Upgraded: Analyst Sees Growth, EBITDA Breakthrough - Inogen ( NASDAQ:INGN )
Analyst upgrades Inogen, citing turnaround progress and margin recovery. Inogen expects EBITDA breakeven in 2025 as DTC sales stabilize. Get 5 'Hidden Gem' stock picks and daily rankings-now 60% off for Memorial Day. Needham analyst Mike Matson upgraded Inogen, Inc INGN from Hold to Buy, with a ...
This United Rentals Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Comerica ( NYSE:CMA ) , Inogen ( NASDAQ:INGN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Mike Matson upgraded the rating for Inogen, Inc.
What Makes Inogen ( INGN ) a New Buy Stock
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
After Plunging -15.69% in 4 Weeks, Here's Why the Trend Might Reverse for Inogen ( INGN )
Inogen (INGN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y
Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.
Inogen ( INGN ) Reports Q1 Loss, Tops Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of 51.92% and 3.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
The medical device industry is growing fast in 2025, but faces supply and trade issues. Major companies are set to report earnings on May 7, stay tuned!
Mettler-Toledo ( MTD ) Q1 Earnings and Revenues Beat Estimates
Mettler-Toledo (MTD) delivered earnings and revenue surprises of 3.67% and 1%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock ...
What's Going On With MedTech Focused Inogen Stock On Wednesday? - Inogen ( NASDAQ:INGN )
Inogen posted a Q4 adjusted EPS loss of $0.24, beating estimates, with sales reaching $80.1 million versus the $73.9 million consensus. The company expects FY25 revenue of $352 million-$355 million, surpassing the consensus of $344.61 million. Our government trade tracker caught Pelosi's 169% AI ...
INGN Stock Gains Following Q4 Earnings Beat, Adjusted Gross Margin Up
Inogen's overall fourth-quarter 2024 results continue to gain from higher business-to-business sales.
Inogen ( INGN ) Reports Q4 Loss, Tops Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of 28.07% and 0.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Fresenius Medical, Masimo, Merit Medical Systems and Inogen
Fresenius Medical, Masimo, Merit Medical Systems and Inogen are included in this Analyst Blog.
What to Expect From These 4 Medical Device Stocks in Q4 Earnings?
Here is a sneak peek into how four Medical Device stocks, namely FMS, MASI, MMSI and INGN, are expected to fare in their quarterly results, slated to be released tomorrow.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
COR Stock Gains on Q1 Earnings & Revenue Beat & Upbeat '25 Outlook
COR's first-quarter fiscal 2025 results showcase a strong segmental performance. The company's sales and earnings guidance for fiscal 2025 looks encouraging.
Reasons to Retain Inari Medical Stock in Your Portfolio for Now
NARI continues to gain from its expanded product portfolio. The company's expansion in China and Japan bodes well.
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Inogen Stock May Gain on Deal With Yuwell to Expand Global Reach
INGN and Yuwell collaborate to expand and enhance Inogen's innovation pipeline through R&D collaboration and accelerate the entry of Inogen's brand into the Chinese market.
Inogen ( INGN ) Moves to Strong Buy: Rationale Behind the Upgrade
Inogen (INGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Inogen Stock Gains Following Solid Preliminary Q4 Revenues
INGN's revenue growth in the fourth quarter is likely to have been boosted by continued robust adoption of its products.
Inogen Stock Rises as FDA Clears SIMEOX 200 Airway Clearance Device
INGN announces FDA clearance for the SIMEOX 200 Airway Clearance Device.
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen
Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.
5 Medical Device Stocks That Survived the 2024 Market Volatility
Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.
Inogen ( INGN ) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Inogen (INGN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
INGN Stock Gains Following Q3 Earnings Beat, Adjusted Gross Margin Up
Inogen's overall third-quarter 2024 results continue to gain from higher business-to-business sales.
Inogen ( INGN ) Reports Q3 Loss, Tops Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of 50.98% and 6.16%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
PROCEPT BioRobotics Corporation ( PRCT ) Reports Q3 Loss, Tops Revenue Estimates
PROCEPT BioRobotics (PRCT) delivered earnings and revenue surprises of 16.67% and 9.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Inogen Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?
INGN shows impressive momentum, driven by strong sales growth, an expanding product portfolio and significant advancements in portable oxygen technology.
Here's Why You Should Add Inogen Stock to Your Portfolio Now - Axogen ( NASDAQ:AXGN ) , Inogen ( NASDAQ:INGN )
Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator ( POC ) space. The optimism, led by solid first-quarter 2024 performance and a strong product portfolio, seems justified.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for the INGN stock.
Can HITI Stock Get a Boost From Bricks-and-Mortar Sales in Q3 Earnings?
Given High Tide's progress in executing its strategic initiatives, we expect it to report robust Q3 bricks-and-mortar segment sales.
Inogen ( INGN ) Rises 127% Year to Date: What's Driving the Stock?
Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.
Inogen Q2 Earnings Beat Estimates, Revenues Rise Y/Y - Inogen ( NASDAQ:INGN )
Inogen, Inc. INGN incurred an adjusted loss per share of 7 cents for the second quarter of 2024, narrower than the adjusted loss per share of 25 cents in the year-ago period. The Zacks Consensus Estimate was pegged at a loss of 54 cents per share.
Inogen ( INGN ) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
Inogen's (INGN) second-quarter 2024 results reflect significant improvement in the top and bottom lines, driven by strong international and domestic business-to-business sales.
Inogen ( INGN ) Reports Q2 Loss, Tops Revenue Estimates
Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Penumbra ( PEN ) Soars 3.3%: Is Further Upside Left in the Stock?
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OrthoPediatrics ( KIDS ) Soars 7.5%: Is Further Upside Left in the Stock?
OrthoPediatrics (KIDS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Reasons to Retain Inogen ( INGN ) Stock in Your Portfolio Now
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
